Geoff MacKay, Avrobio CEO
December 7, 2022 11:21 AM EST
R&D
Cell/Gene Tx

Avro­bio touts ear­ly clin­i­cal da­ta and plans new gene ther­a­py tri­al in 2023

Katherine Lewin

News Reporter

Those with Gauch­er dis­ease have to prac­ti­cal­ly live at the hos­pi­tal to re­ceive bi-week­ly, hours-long in­fu­sions of en­zyme re­place­ment ther­a­py — for the rest of their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times